In the Atg5-deficient prostate cancer cell line DU-145, sorafenib could mediate necroptosis by inducing the RIPK1/RIPK3/MLKL pathway, and this process can be blocked by the RIPK1 inhibitor Nec-1 (Heidaryan et al., 2020). Here, RIPK1 is linked to Familial prostate cancer.